The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.
Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal
RECENT NEWS
Sorry, but the ‘drugs from Canada’ don’t work
“Drugs from Canada” is a policy that won’t work. And a political soundbite that won’t die.... Read more
Product Failure Is Not Process Failure
FDA be nimble. FDA be quick. FDA jump over the bureaucratic schtick.... Read more
The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region
Congress must enact legislation that pushes our country forward, builds bridges where there are gaps, and leverages strat... Read more